Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Myvac

New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023

New Data Showing that Transgene and NEC’s TG4050 induces strong and specific immune responses against tumors presented at AACR 15

Published 18 April 2023
Categorized as 2023, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)

JP Delord, et al. ASCO 2022 Abstract available on the ASCO website – Download the poster here Poster Presentation

Published 6 June 2022
Categorized as 2022, Myvac, Publication, TG4050

Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022

Transgene presented additional Phase I Data with TG4050 at ASCO 2022

Published 6 June 2022
Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022

Transgene to present updated positive preliminary data at ASCO 2022

Published 27 May 2022
Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

MS Block et al. AACR 2022 Download the publication here

Published 12 April 2022
Categorized as 2022, Myvac, TG4050

Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

MS Block et al.AACR 2022Read the abstract here – Download the poster herePoster Presentation

Published 8 April 2022
Categorized as 2022, Myvac, Publication, TG4050

Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050

Transgene to present new positive preliminary Phase I Clinical data

Published 8 April 2022
Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022

Transgene to present new positive preliminary Phase I data on TG4050

Published 9 March 2022
Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

Published 28 June 2021
Categorized as 2021, dates, Myvac, Press release, TG4050

Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences

20210302 – Transgene Scientific Conferences

Published 2 March 2021
Categorized as 2021, Invir.IO, Myvac, Press release

Posts pagination

Newer posts Page 1 … Page 5 … Page 7 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu